<SEC-DOCUMENT>0001096906-26-000602.txt : 20260423
<SEC-HEADER>0001096906-26-000602.hdr.sgml : 20260423
<ACCEPTANCE-DATETIME>20260423154947
ACCESSION NUMBER:		0001096906-26-000602
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20260423
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260423
DATE AS OF CHANGE:		20260423

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UTAH MEDICAL PRODUCTS INC
		CENTRAL INDEX KEY:			0000706698
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				870342734
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12575
		FILM NUMBER:		26888299

	BUSINESS ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84070
		BUSINESS PHONE:		8015215301

	MAIL ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84047
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>utmd-20260423_8k.htm
<DESCRIPTION>UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:fil="http://utahmed.com/20260423" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:i="http://www.xbrl.org/2003/instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<head>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VAU9GXSW]. www.edgarsuite.com -->
<title>UTAH MEDICAL PRODUCTS, INC. - Form 8-K SEC filing</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body>
<div style="display:none">
<ix:header>
<ix:hidden>
<ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="D260423" id="fact1">0000706698</ix:nonNumeric>
<ix:nonNumeric name="dei:AmendmentFlag" contextRef="D260423" id="fact2">false</ix:nonNumeric>
</ix:hidden>
<ix:references>
	<link:schemaRef xlink:type="simple" xlink:href="utmd-20260423.xsd"/>
</ix:references>
<ix:resources>
<i:context id="D260423">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2026-04-23</i:startDate>
<i:endDate>2026-04-23</i:endDate>
</i:period>
</i:context>
</ix:resources>
</ix:header>
</div>
<div style="margin-left:72pt;width:468pt"><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:14pt Times New Roman;margin:0;text-align:center"><b>UNITED STATES </b></p>
<p style="font:14pt Times New Roman;margin:0;text-align:center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style="font:15pt Times New Roman;margin:0;text-align:center"><b>Washington, D.C. &#160;20549</b></p>
<p style="font:15pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:center"><span style="font-size:14pt"><b>FORM </b><b><ix:nonNumeric name="dei:DocumentType" contextRef="D260423" escape="true" id="ixv-337">8-K</ix:nonNumeric></b></span></p>
<p style="font:14pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:14pt Times New Roman;margin:0;text-align:center"><b>CURRENT REPORT</b></p>
<p style="font:14pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:12pt Times New Roman;margin:0;text-align:center"><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">Date of Report (date of earliest event reported): <b><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="D260423" format="ixt:date-monthname-day-year-en" id="ixv-338">April 23, 2026</ix:nonNumeric></b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:14pt"><b><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="D260423" escape="true" id="ixv-339">UTAH MEDICAL PRODUCTS, INC.</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">(Exact name of registrant as specified in its charter)</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="D260423" escape="true" id="ixv-340">UT</ix:nonNumeric>AH</b></p>
</td><td valign="top" style="width:2.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b><ix:nonNumeric name="dei:EntityFileNumber" contextRef="D260423" escape="true" id="ixv-341">000-12575</ix:nonNumeric></b></p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="D260423" escape="true" id="ixv-342">87-0342734</ix:nonNumeric></b></p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(State or other jurisdiction of</p>
</td><td valign="top" style="width:2.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(Commission File Number)</p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(IRS Employer</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">incorporation or organization)</p>
</td><td valign="top" style="width:2.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">Identification No.)</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="D260423" escape="true" id="ixv-343">7043 South 300 West</ix:nonNumeric></b></p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="D260423" escape="true" id="ixv-344">Midvale</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="D260423" format="ixt-sec:stateprovnameen" id="ixv-345">Utah</ix:nonNumeric></b></p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="D260423" escape="true" id="ixv-346">84047</ix:nonNumeric></b></p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(Address of principal executive offices)</p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(Zip code)</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0">Registrant&#8217;s telephone number, including area code: &#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>Phone: (<ix:nonNumeric name="dei:CityAreaCode" contextRef="D260423" escape="true" id="ixv-347">801</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="D260423" escape="true" id="ixv-348">566-1200</ix:nonNumeric></b></p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>n/a</b></p>
</td></tr>
<tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(Former name or former address, if changed since last report)</p>
</td></tr>
</table>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse"><tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="D260423" format="ixt-sec:boolballotbox" id="ixv-349">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="D260423" format="ixt-sec:boolballotbox" id="ixv-350">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="D260423" format="ixt-sec:boolballotbox" id="ixv-351">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="D260423" format="ixt-sec:boolballotbox" id="ixv-352">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:478.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="D260423" format="ixt-sec:boolballotbox" id="ixv-353">&#9744;</ix:nonNumeric></p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:478.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:478.8pt"><p style="font:10pt Times New Roman;margin:0">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:Wingdings"><span style="font-family:Wingdings">&#168;</span></span></p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0"><b>ITEM 2.02&#8212;RESULTS OF OPERATIONS AND FINANCIAL CONDITION</b></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:72pt;text-align:justify">Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three months ended March 31, 2026 and forward-looking statements relating to 2026 and beyond as presented in a press release dated April 23, 2026. &#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:72pt">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:72pt;text-align:justify">The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:90pt">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><b>ITEM 9.01&#8212;FINANCIAL STATEMENTS AND EXHIBITS</b></p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">The following is filed as an exhibit to this report: &#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:12.56%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>Exhibit</b></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><b>Number*</b></p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:69.22%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><b>Title of Document</b></p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:12.98%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><b>Location</b></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:12.56%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>Item 99.1</b></p>
</td><td valign="top" style="background-color:#CCEEFF;width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:69.22%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex99z1.htm" style="text-decoration:none">Financial information for Utah Medical Products, Inc. for the three months ended March 31, 2026 and forward-looking statements relating to 2026 and beyond as presented in a press release dated April 23, 2026.</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.98%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:12.56%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:69.22%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:12.98%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">This filing</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">_______________________________________</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:18pt;text-align:justify"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">*</kbd>All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document. &#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><b>SIGNATURES</b></p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse"><tr><td valign="top" style="width:234.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><b>UTAH MEDICAL PRODUCTS, INC.</b></p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Dated: &#160;April 23, 2026</p>
</td><td valign="top" style="width:26.7pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">By:</p>
</td><td valign="top" style="width:218.05pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:justify">/s/ Kevin L. Cornwell</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:26.7pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:218.05pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Kevin L. Cornwell, Chief Executive Officer</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/></div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>utmd_ex99z1.htm
<DESCRIPTION>FINANCIAL INFORMATION FOR UTAH MEDICAL PRODUCTS, INC. FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND FORWARD-LOOKING STATEMENTS RELATING TO 2026 AND BEYOND AS PRESENTED IN A PRESS RELEASE DATED APRIL 23, 2026.
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VAU9GXSW]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'><B>EXHIBIT 99.1</B></P>
<P align=center style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'><B>Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2026</B></P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:50%><P style='font:11pt Times New Roman;margin:0'>Contact: Brian Koopman (801) 566-1200</P>
</TD><TD valign=top style=width:50%><P align=right style='font:11pt Times New Roman;margin:0'>April 23, 2026</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Salt Lake City, Utah &#8211;&nbsp;In the first calendar quarter (1Q) of 2026, Utah Medical Products, Inc. (Nasdaq: UTMD) attained financial results which were consistent with its previously announced projections for calendar year 2026. &nbsp;But because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results for the year as a whole.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Summary of results</FONT>.</P>
<P style='font:11pt Times New Roman;margin:0'>The following is a summary comparison of 1Q 2026 with 1Q 2025 income statement measures:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top bgcolor=#CCEEFF style=width:80.28%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Revenues (Sales):</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:19.72%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'> &nbsp;&nbsp;(10.2%)</P>
</TD></TR>
<TR><TD valign=top style=width:80.28%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Gross Profit (GP):</P>
</TD><TD valign=top style=width:19.72%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'> &nbsp; ( 4.6%)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:80.28%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Operating Income (OI):</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:19.72%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'> &nbsp;(18.7%)</P>
</TD></TR>
<TR><TD valign=top style=width:80.28%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Net Income (NI):</P>
</TD><TD valign=top style=width:19.72%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'> &nbsp;&nbsp;(14.4%)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:80.28%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Earnings Per Share (EPS):</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:19.72%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'> &nbsp;&nbsp;(11.0%)</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:60.66%><P style='font:11pt Times New Roman;margin:0;text-indent:-5.65pt;margin-right:-6.3pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Profit margins in 1Q 2026 compared to 1Q 2025 follow:</P>
</TD><TD valign=top style=width:19.68%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>1Q 2026</P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'><FONT style='border-bottom:1px solid #000000'>(JAN &#8211;&nbsp;MAR)</FONT></P>
</TD><TD valign=top style=width:19.66%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>1Q 2025</P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'><FONT style='border-bottom:1px solid #000000'>JAN - MAR</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:60.66%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Gross Profit Margin (gross profits/ sales):</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:19.68%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>60.6%</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:19.66%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>57.0%</P>
</TD></TR>
<TR><TD valign=top style=width:60.66%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Operating Income Margin (operating income/ sales):</P>
</TD><TD valign=top style=width:19.68%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>29.4%</P>
</TD><TD valign=top style=width:19.66%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>32.5%</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:60.66%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>EBT Margin (profits before income taxes/ sales):</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:19.68%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>36.5%</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:19.66%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>39.7%</P>
</TD></TR>
<TR><TD valign=top style=width:60.66%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.25pt'>Net Income Margin (profit after taxes/ sales):</P>
</TD><TD valign=top style=width:19.68%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>29.9% </P>
</TD><TD valign=top style=width:19.66%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>31.3% </P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; &#163;&nbsp;or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and &#8364;&nbsp;or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Consolidated sales in 1Q 2026 were $987 lower than in 1Q 2025. As expected and previously reported, UTMD did not have any 1Q 2026 sales to its previous largest medical device distributor of blood pressure monitoring kits in China, or to its previous OEM customer, PendoTECH. &nbsp;The combined sales to those two entities in 1Q 2025 were $857, representing 87% of the lower 1Q 2026 sales. Although overall domestic sales were about the same in both 1Q 2026 and 2025, sales outside the U.S. (OUS) excluding the China distributor were another $176 lower, due to lower Filshie Clip System sales OUS. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Using the same foreign currency exchange (FX) rates for sales not invoiced in USD, i.e. in &#8220;constant currency&#8221; terms, OUS sales would have been an additional $169 lower because of a weaker USD. FX rates for income statement purposes are transaction-weighted averages. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>The average FX rates from the applicable foreign currency to USD during 1Q 2026 and 1Q 2025 follow:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:42.98%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:17.6%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1Q 2026</FONT></P>
</TD><TD valign=top style=width:19.7%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1Q 2025</FONT></P>
</TD><TD valign=top style=width:19.72%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:42.98%><P style='font:11pt Times New Roman;margin:0'>GBP</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.6%><P align=center style='font:11pt Times New Roman;margin:0'>1.348</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:19.7%><P align=center style='font:11pt Times New Roman;margin:0'>1.261</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:19.72%><P align=center style='font:11pt Times New Roman;margin:0'>+6.9%</P>
</TD></TR>
<TR><TD valign=top style=width:42.98%><P style='font:11pt Times New Roman;margin:0'>EUR</P>
</TD><TD valign=top style=width:17.6%><P align=center style='font:11pt Times New Roman;margin:0'>1.165</P>
</TD><TD valign=top style=width:19.7%><P align=center style='font:11pt Times New Roman;margin:0'>1.073</P>
</TD><TD valign=top style=width:19.72%><P align=center style='font:11pt Times New Roman;margin:0'>+8.5%</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:42.98%><P style='font:11pt Times New Roman;margin:0'>AUD</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.6%><P align=center style='font:11pt Times New Roman;margin:0'>0.698</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:19.7%><P align=center style='font:11pt Times New Roman;margin:0'>0.628</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:19.72%><P align=center style='font:11pt Times New Roman;margin:0'>+11.1%</P>
</TD></TR>
<TR><TD valign=top style=width:42.98%><P style='font:11pt Times New Roman;margin:0'>CAD</P>
</TD><TD valign=top style=width:17.6%><P align=center style='font:11pt Times New Roman;margin:0'>0.730</P>
</TD><TD valign=top style=width:19.7%><P align=center style='font:11pt Times New Roman;margin:0'>0.697</P>
</TD><TD valign=top style=width:19.72%><P align=center style='font:11pt Times New Roman;margin:0'>+4.7%</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD&#8217;s 1Q 2026 GP at $5,282 was $256 lower than 1Q 2025 GP of $5,538. The 4.6% lower GP was less than the 10.2% decline in sales as a result of a more favorable product mix and a yearly one-time adjustment to standard costs which increased inventory value. Historically, sales to UTMD&#8217;s largest OUS distributor in China had a significantly lower GP Margin (GPM), GP/Revenues, than UTMD&#8217;s average </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style=font-size:11pt>GPM. &nbsp;Although manufacturing overhead costs were higher, which should lower the GPM when sales are lower, UTMD continues to effectively manage its variable manufacturing expenses. &nbsp;&nbsp;</FONT></P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Consolidated worldwide (WW) OI, which is GP less Operating Expense (OE), in 1Q 2026 at $2,565 (29.4% of sales) was $588 lower than 1Q 2025 OI of $3,154 (32.5% of sales). &nbsp;OI was $332 lower in addition to the $256 lower GP, due to $127 higher litigation expenses, $147 higher employee health care costs in U.S. General and Administrative (G&amp;A) expense and $65 higher same foreign currency exchange rate of OUS OE due to a weaker USD. &nbsp;In the aggregate, the components of WW OE in USD terms were Product Development (R&amp;D) expenses about the same, Sales &amp; Marketing (S&amp;M) expenses $19 higher and G&amp;A expenses $314 higher than in 1Q 2025, respectively. &nbsp;&nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Income Before Tax (EBT) declined more than the $588 lower OI because net non-operating income (NOI) in 1Q 2026 was just $617 compared to $705 in 1Q 2025. The lower NOI was due to lower interest earned on cash balances. Combining the $588 lower OI with the about $89 lower NOI yielded 1Q 2026 EBT $677 (17.5%) lower than in 1Q 2025. UTMD&#8217;s EBT Margin (EBT/sales) was 36.5% in 1Q 2026 compared to 39.7% in 1Q 2025. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD&#8217;s consolidated income tax provision rate in 1Q 2026 was 18.2% compared to 21.2% in 1Q 2025. An EBT mix difference among subsidiary sovereignties caused the provision rate difference. The basic corporate income tax rate for the U.S. (including Utah state income tax) is 25.45% and for Ireland on EBT from exports is 12.5%. The lower income tax provision rate offset the 17.5% lower EBT, resulting in 1Q 2026 NI that was 14.4% lower than in 1Q 2025. Fewer outstanding shares as a result of UTMD&#8217;s share repurchases further reduced the decline in 1Q 2026 earnings per share (EPS), which is NI/diluted number of outstanding shares, to be just 11.0% lower than in 1Q 2025. During the four calendar quarters following the end of 1Q 2025, UTMD repurchased 96,864 of its shares in the open market. There was no dilution from outstanding employee stock options for purposes of calculating diluted EPS in either 1Q 2026 or 1Q 2025. &nbsp;In income statement summary, with the top line declining 10.5% in 1Q 2026 compared to 1Q 2025, EPS declined 11.0%. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD&#8217;s March 31, 2026 Balance Sheet, in the absence of debt, remained strong. After using $9.5 million in cash during the most recent twelve-month period to make share repurchases, pay stockholder dividends and purchase new equipment, UTMD&#8217;s March 31, 2026 cash equivalent balances were $4.1 million higher than at March 31, 2025. &nbsp;Ending 1Q 2026 cash equivalent balances were about $1.7 million higher than three months earlier at December 31, 2025.  Stockholders&#8217; Equity (SE) at $120.4 million improved $1.1 million at the end of 1Q 2026 from three months earlier, despite the fact that dividends and share repurchases reduce SE. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>FX rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 1Q 2026 and the end of 1Q 2025 follow:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:43.08%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:17.5%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3-31-26</FONT></P>
</TD><TD valign=top style=width:19.9%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3-31-25</FONT></P>
</TD><TD valign=top style=width:19.52%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:43.08%><P style='font:11pt Times New Roman;margin:0'>GBP</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=center style='font:11pt Times New Roman;margin:0'>1.318</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:19.9%><P align=center style='font:11pt Times New Roman;margin:0'>1.289</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:19.52%><P align=center style='font:11pt Times New Roman;margin:0'>2.3%</P>
</TD></TR>
<TR><TD valign=top style=width:43.08%><P style='font:11pt Times New Roman;margin:0'>EUR</P>
</TD><TD valign=top style=width:17.5%><P align=center style='font:11pt Times New Roman;margin:0'>1.152</P>
</TD><TD valign=top style=width:19.9%><P align=center style='font:11pt Times New Roman;margin:0'>1.079</P>
</TD><TD valign=top style=width:19.52%><P align=center style='font:11pt Times New Roman;margin:0'>6.7%</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:43.08%><P style='font:11pt Times New Roman;margin:0'>AUD</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=center style='font:11pt Times New Roman;margin:0'>0.685</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:19.9%><P align=center style='font:11pt Times New Roman;margin:0'>0.624</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:19.52%><P align=center style='font:11pt Times New Roman;margin:0'>9.9%</P>
</TD></TR>
<TR><TD valign=top style=width:43.08%><P style='font:11pt Times New Roman;margin:0'>CAD</P>
</TD><TD valign=top style=width:17.5%><P align=center style='font:11pt Times New Roman;margin:0'>0.717</P>
</TD><TD valign=top style=width:19.9%><P align=center style='font:11pt Times New Roman;margin:0'>0.695</P>
</TD><TD valign=top style=width:19.52%><P align=center style='font:11pt Times New Roman;margin:0'>3.0%</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Sales</FONT>. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Total consolidated 1Q 2026 UTMD sales were $987 (10.2%) lower than in 1Q 2025. Constant currency sales were $1,156 (11.9%) lower. U.S. domestic sales were 0.4% lower, and OUS sales were 23.4% lower.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Domestic sales in 1Q 2026 were almost the same at $5,560 compared to $5,583 in 1Q 2025. &nbsp;The components of domestic sales include 1) &#8220;direct sales&#8221; of UTMD&#8217;s medical devices to user facilities (and med/surg stocking distributors for hospitals), excluding Filshie device sales, 2) &#8220;OEM sales&#8221; of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) &#8220;Filshie device sales&#8221;, manufactured by Femcare and distributed in the U.S. by UTMD. </P>
<P style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>1)</KBD>Direct medical device sales, representing 61% of total domestic sales, were $503 (12.8%) lower in 1Q 2026 than in 1Q 2025. Sales were lower in all product categories in what was hopefully just an abnormally weak demand quarter. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>2)</KBD>Total domestic OEM sales in 1Q 2026, representing 11% of all domestic sales, were $13 (2.1%) lower than in 1Q 2025, as the final $69 order backlog to PendoTECH was shipped in 1Q 2025. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>3)</KBD>Domestic Filshie device sales, representing 28% of all domestic sales, were $493 (+47.4%) higher in 1Q 2026 compared to 1Q 2025, which appears to be an abnormally high U.S. medical facility demand quarter.  &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>OUS sales in 1Q 2026 were $965 (23.4%) lower at $3,162 compared to $4,127 in 1Q 2025. &nbsp;Sales to UTMD&#8217;s former distributor in China which were $789 in 1Q 2025 (and zero in 1Q 2026), which explains 82% of the $965 lower OUS sales. Although Filshie device sales directly to medical facilities in Ireland and the UK were about the same in both periods, direct Filshie device sales to medical facilities in Canada, France and Australia were $230 lower. OUS foreign currency sales actually benefited $169 from a weaker USD. On a constant currency basis, 1Q 2026 OUS sales were $1,133 (27.5%) lower than in 1Q 2025. OUS sales invoiced in foreign currencies in 1Q 2026 were $2,327, which was 74% of all OUS sales, and 27% of total 1Q 2026 UTMD consolidated sales. &nbsp;Foreign currency OUS sales in 1Q 2025 were $2,944, which was 71% of all OUS sales and 30% of total 1Q 2025 UTMD consolidated sales. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Gross Profit (GP)</FONT>. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>UTMD&#8217;s 1Q 2026 GP was $256 (4.6%) lower in 1Q 2026 than in 1Q 2025, driven by 10.2% lower sales. GP results from subtracting the costs of manufacturing products, including direct labor, raw materials and manufacturing overhead (MOH) expenses, from revenues. MOH, which was higher due primarily to cost-of-living adjustments for employees, includes supervision, engineering, quality assurance, outside services, depreciation of manufacturing equipment, purchasing and freight for receiving raw materials from vendors.  Higher MOH expense with lower sales decreases the GPM. &nbsp;Nevertheless, UTMD&#8217;s average GPM in 1Q 2026 was 60.6% compared to 57.0% in 1Q 2025. Although the lack of low GPM sales to UTMD&#8217;s former China distributor helped to improve the average GPM, the margin increase was further leveraged by an annual standard cost adjustment after the end of 2025, which increased the book value of inventories. As a side note, UTMD in the U.S. distributes Filshie devices direct to U.S. medical facilities, which are manufactured by its Ireland subsidiary. Tariffs paid to the U.S. government on Filshie devices purchased from UTMD&#8217;s own subsidiary &#8220;off the top&#8221; of intercompany sales were $108 higher in 1Q 2026 compared to 1Q 2025. This had the equivalent financial effect of raising UTMD&#8217;s federal income tax rate in the U.S., thus lowering consolidated net income and EPS, which does not increase UTMD U.S. stockholder value to be sure. &nbsp; &nbsp;  </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Operating Income (OI)</FONT>. </P>
<P style='font:11pt Times New Roman;margin:0'>OI results from subtracting Operating Expenses (OE) from GP. OI of $2,565 in 1Q 2026 was $588 (18.7%) lower than the $3,154 OI in 1Q 2025. OE is comprised of G&amp;A expenses, S&amp;M expenses and R&amp;D expenses. Consolidated OE were $2,717 in 1Q 2026 (31.1% of sales) compared to $2,385 in 1Q 2025 (24.6% of sales). The substantial $332 increase in 1Q 2026 OE came predominantly from a $314 increase in 1Q 2026 G&amp;A expenses.</P>
<P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Consolidated G&amp;A expenses were $2,044 (23.4% of sales) in 1Q 2026 compared to $1,730 (17.8% of sales) in 1Q 2025. The $314 increase in G&amp;A expenses came from three causes: 1) U.S. G&amp;A employee health care cost, 2) litigation expense, and 3) the effect of a weaker USD when translating foreign currency subsidiary G&amp;A expenses. Net other G&amp;A expenses were slightly lower.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>1)</KBD>UTMD in the U.S. self-insures its health care plan, where costs are typically driven by a small portion of employees when a major claim occurs. U.S. G&amp;A heath care costs were $147 higher in 1Q 2026 than in 1Q 2025. &nbsp;Although not predictable, UTMD expects the remainder of year 2026 experience should be more like 2025.&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>2)</KBD>Although UTMD has now won 15 of 19 court case dismissals, a confluence of litigation deadlines in 1Q 2026 necessitated significant legal work in the remaining few. Although litigation expense in 1Q 2026 was $127 higher than in 1Q 2025, UTMD continues to expect litigation expense for the 2026 year will be less than for the 2025 year. This of course assumes that, as has been the experience so far, no case goes to trial.&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>3)</KBD>Constant currency G&amp;A expenses of foreign subsidiaries were $56 higher due to a weaker USD in 1Q 2026 compared to 1Q 2025. &nbsp;A $29 portion of that $56 was due to translation of identifiable intangible asset (IIA) amortization expense resulting from the 2011 Femcare acquisition, which was completed in 1Q 2026. As a side note, the 1Q 2026 IIA amortization expense, which will be zero in ensuing 2026 quarters, was $458.&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>S&amp;M expenses were $519 (5.9% of sales) in 1Q 2026 compared to $500 (5.1% of sales) in 1Q 2025. &nbsp;The change in FX rates increased 1Q 2026 OUS S&amp;M expenses by $9. &nbsp;The remaining increase was due to increases in <A name=_Hlk164328705 />S&amp;M salaries. Consequently, more than half of higher S&amp;M expense percentage of sales was due to lower sales.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>R&amp;D expenses in 1Q 2026 were $154 (1.8% of sales) compared to $155 (1.6% of sales) in 1Q 2025. &nbsp;There were no OUS R&amp;D expenses.   </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Income Before Tax (EBT).</FONT> &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>EBT results from subtracting net non-operating expense (NOE) or adding net non-operating income (NOI) from or to, as applicable, OI. Consolidated 1Q 2026 EBT was $3,181 (36.5% of sales) compared to $3,859 (39.73% of sales) in 1Q 2025. The $677 (17.5%) lower 1Q 2026 EBT compared to 1Q 2025 was the result of $588 lower OI combined with $89 lower NOI. NOE/NOI includes the combination of 1) expenses from loan interest and bank fees; 2) expenses or income from losses or gains from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms; and 3) income from rent of underutilized property, investment income and royalties received from licensing the Company&#8217;s technology. NOI in 1Q 2026 included $106 lower interest income on UTMD&#8217;s cash balances. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>The EBT of Utah Medical Products, Inc. in the U.S. was $2,825 in 1Q 2026 compared to $3,546 in 1Q 2025. The EBT of Utah Medical Products, Ltd (Ireland) was EUR 1,164 in 1Q 2026 compared to EUR 1,393 in 1Q 2025. The EBT of Femcare Group Ltd (Femcare Ltd., UK and Femcare Australia Pty Ltd) was GBP (686) in 1Q 2026 compared to GBP (663) in 1Q 2025. The 1Q 2026 EBT of Utah Medical Products Canada, Inc. was CAD (37) compared to CAD 107 in 1Q 2025. &nbsp;The differences in the U.S. and UK EBT were accentuated by intercompany transfer of litigation expenses which did not affect consolidated results.  </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 1Q 2026 consolidated EBT excluding the remeasured bank balance currency gain or loss and interest expense (&#8220;adjusted consolidated EBITDA&#8221;) were $3,982 compared to $4,652 in 1Q 2025.  UTMD&#8217;s trailing twelve-month EBITDA as of March 31, 2026 was $16,788. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Net Income (NI)</FONT>. </P>
<P style='font:11pt Times New Roman;margin:0'>NI in 1Q 2026 of $2,604 was $438 (14.4%) lower than the NI of $3,041 in 1Q 2025. UTMD&#8217;s NI Margin, NI divided by consolidated sales, was 29.9% in 1Q 2026 and 31.3% in 1Q 2025. The smaller &nbsp;14.4% NI decline compared to 17.5% lower EBT was due to average consolidated income tax provision rates (as a % of EBT) in 1Q 2026 of 18.2% and 21.2% in 1Q 2025. &nbsp;Although basic corporate income tax rates did not change, the consolidated income tax provision can vary from period-to-period depending on the portion of EBT in sovereignties with differing rates, and a periodic true-up when actual tax returns are filed.  &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Earnings per share (EPS)</FONT>. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>EPS in 1Q 2026 at $0.818 were 11.0% lower than the $0.919 in 1Q 2025. &nbsp;UTMD&#8217;s smaller decline in EPS relative to NI was a result of 125,265 fewer diluted shares used to calculate EPS in 1Q 2026 compared to 1Q 2025. Diluted shares were 3,184,983 in 1Q 2026 compared to 3,310,248 in 1Q 2025. &nbsp;Outstanding shares were 3,184,025 at the end of 1Q 2026. The number of shares used for calculating EPS was higher than ending shares because of a time-weighted calculation of average outstanding shares for shares which were repurchased during the quarter. There was no dilution from unexercised employee options in either 1Q 2026 or 1Q 2025 as the average option exercise prices were above the period-ending closing stock prices. The total number of outstanding unexercised employee and outside director options at March 31, 2026 was 121,085 at an average exercise price of $70.66, including shares awarded but not yet vested. This compares to 97,779 unexercised option shares at the end of 1Q 2025 at an average exercise price of $73.77/ share, including shares awarded but not vested. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Outstanding shares at the end of 1Q 2026 were 3,184,025 compared to 3,186,221 at the end of calendar year 2025 and 3,280,889 at the end of 1Q 2025. The difference in outstanding shares at the end of 1Q 2026 compared to the end of 2025 resulted from 2,196 shares repurchased in the open market, with no employee options exercised, during 1Q 2026.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD repurchased 2,196 of its shares at an average price of $58.58 during 1Q 2026. Because of a time-weighted calculation, the full antidilution impact of the 1Q 2026 repurchases won&#8217;t be felt until 2Q 2026. There were 54,267 share repurchases in 1Q 2025 at an average price of $59.35. No options were awarded in 1Q 2026 or 1Q 2025. During the rest of 2025 after 1Q 2025, 13,800 option shares were awarded to 40 employees at an exercise price of $58.10. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders. UTMD&#8217;s closing share price at the end of 1Q 2026 was $61.99, up 11% from the $55.96 closing price three months earlier at the end of 2025. The closing share price at the end of 1Q 2025 was $56.04. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD paid $989 ($0.31/share) in cash dividends to stockholders in 1Q 2026. UTMD paid $1,017 ($0.305/share) in cash dividends to stockholders in 1Q 2025. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Balance Sheet</FONT>.</P>
<P style='font:11pt Times New Roman;margin:0'>At March 31, 2026 compared to three months earlier at the end of 2025, UTMD&#8217;s cash and investments increased $1,649 to $87,406, despite use of $129 cash to repurchase shares, pay $989 in stockholder dividends and purchase $130 in additional capital equipment. Compared to a year earlier at March 31, 2025, cash and investments increased $4,081. At March 31, 2026, net Intangible Assets declined $610 to 11.5% of total consolidated assets from 12.2% on December 31, 2025. &nbsp;The decline in Net Intangible Assets from a year earlier was $1,893. &nbsp;Inventories increased $787 from the end of 2025, and $75 from a year earlier. Working capital at the end of 1Q 2026 was $1,730 higher than at the end of 2025, and $4,798 higher than at March 31, 2025. UTMD&#8217;s current ratio improved to 28.6 at March 31, 2026 from 22.3 at March 31, 2025. &nbsp;The current ratio at the end of 2025 was 37.6 due to low end-of-year current liabilities. Consolidated Accounts Receivable (net of allowances) increased $115 at March 31, 2026 from the end of 2025, but decreased $307 compared to March 31, 2025 due to lower sales. On a rolling sales quarter basis, the aging of receivables were 37.5 days at the end of 1Q 2026, compared to 35.0 days at the end of 2025 and 36.6 days at the end of March 2025, all well within management targets.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>As of March 31, 2026, Stockholders&#8217; Equity (SE) increased $3,325 to $120,373 compared to a year earlier at March 31, 2025, despite a reduction in SE from the $9,218 combination of share repurchases and stockholder cash dividends paid during the last twelve months. &nbsp;During 1Q 2026, SE increased $1,105 from the end of 2025 while the company paid $989 in dividends and repurchased $129 in stock, which reduced SE.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Financial ratios as of March 31, 2026 which may be of interest to stockholders follow:</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>1)</KBD>Current Ratio = 28.6&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>2)</KBD>Days in Trade Receivables (based on 1Q 2026 sales activity) = 37.5&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>3)</KBD>Average Inventory Turns (based on 1Q 2026 CGS) = 1.7&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>4)</KBD>2026 YTD ROE (before dividends) = 8.7%&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Investors are cautioned that this press release contains forward looking statements and that actual events may differ from those projected. &nbsp;Risk factors that could cause results to differ materially from those projected include global economic conditions and potential trade wars, market acceptance of products, regulatory approvals of products, regulatory intervention in current operations, government intervention in healthcare and the economy in general, tax reforms, the Company&#8217;s ability to efficiently manufacture, market and sell products, cybersecurity and foreign currency exchange rates, among other factors that have been and will be outlined in UTMD&#8217;s public disclosure filings with the SEC.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over one hundred countries around the world as the standard for obtaining optimal long-term outcomes for their patients. &nbsp;For more information about Utah Medical Products, Inc., visit UTMD&#8217;s website at<B><I> </I></B><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><B><I>www.utahmed.com</I></B></FONT>.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:12pt Times New Roman;margin-top:8pt;margin-bottom:4pt;color:#0F4761'><FONT style=color:#000000><I>Utah Medical Products, Inc.</I></FONT></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt'>INCOME STATEMENT, First Quarter ended March 31 </P>
<P style='font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt'>(in thousands except Earnings Per Share)</P>
<P style='font:11pt Times New Roman;margin:0;text-indent:-18pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:48.56%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1Q 2026</FONT></P>
</TD><TD valign=top style=width:16.64%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1Q 2025</FONT></P>
</TD><TD valign=top style=width:17.3%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Percent Change</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:48.56%><P style='font:11pt Times New Roman;margin:0'>Net Sales</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>$8,722</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:16.64%><P align=right style='font:11pt Times New Roman;margin:0'>$9,710</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.3%><P align=right style='font:11pt Times New Roman;margin:0'>(10.2%)</P>
</TD></TR>
<TR><TD valign=top style=width:48.56%><P style='font:11pt Times New Roman;margin:0'>Gross Profit</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>5,282</P>
</TD><TD valign=top style=width:16.64%><P align=right style='font:11pt Times New Roman;margin:0'>5,538</P>
</TD><TD valign=top style=width:17.3%><P align=right style='font:11pt Times New Roman;margin:0'>(4.6%)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:48.56%><P style='font:11pt Times New Roman;margin:0'>Operating Income</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>2,565</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:16.64%><P align=right style='font:11pt Times New Roman;margin:0'>3,154</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.3%><P align=right style='font:11pt Times New Roman;margin:0'>(18.7%)</P>
</TD></TR>
<TR><TD valign=top style=width:48.56%><P style='font:11pt Times New Roman;margin:0'>Income Before Tax</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>3,182</P>
</TD><TD valign=top style=width:16.64%><P align=right style='font:11pt Times New Roman;margin:0'>3,859</P>
</TD><TD valign=top style=width:17.3%><P align=right style='font:11pt Times New Roman;margin:0'>(17.5%)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:48.56%><P style='font:11pt Times New Roman;margin:0'>Net Income</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>2,604</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:16.64%><P align=right style='font:11pt Times New Roman;margin:0'>3,041</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.3%><P align=right style='font:11pt Times New Roman;margin:0'>(14.4%)</P>
</TD></TR>
<TR><TD valign=top style=width:48.56%><P style='font:11pt Times New Roman;margin:0'>Earnings Per Share</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>$0.818</P>
</TD><TD valign=top style=width:16.64%><P align=right style='font:11pt Times New Roman;margin:0'>$0.919</P>
</TD><TD valign=top style=width:17.3%><P align=right style='font:11pt Times New Roman;margin:0'>(11.0%)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:48.56%><P style='font:11pt Times New Roman;margin:0'>Shares Outstanding (diluted)</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>3,185</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:16.64%><P align=right style='font:11pt Times New Roman;margin:0'>3,310</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.3%><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;color:#0F4761'><FONT style=color:#000000><B>BALANCE SHEET</B></FONT></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:48.48%><P style='font:11pt Times New Roman;margin:0'>(in thousands)</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>(unaudited) &nbsp;</P>
<P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>MAR 31, 2026</FONT></P>
</TD><TD valign=top style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>(audited)</P>
<P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>DEC 31, 2025</FONT></P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>(unaudited)</P>
<P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>MAR 31, 2025</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:48.48%><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Assets</FONT></P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:48.48%><P style='font:11pt Times New Roman;margin:0'> &nbsp;Cash &amp; Investments</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>$ 87,406</P>
</TD><TD valign=top style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>$ 85,756</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>$ 83,325</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:48.48%><P style='font:11pt Times New Roman;margin:0'> &nbsp;Accounts &amp; Other Receivables, Net</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>3,636</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>3,522</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>3,944</P>
</TD></TR>
<TR><TD valign=top style=width:48.48%><P style='font:11pt Times New Roman;margin:0'> &nbsp;Inventories</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>8,722</P>
</TD><TD valign=top style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>7,935</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>8,647</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:48.48%><P style='font:11pt Times New Roman;margin:0'> &nbsp;Other Current Assets</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>614</FONT></P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>529</FONT></P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>483</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:48.48%><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>100,378</P>
</TD><TD valign=top style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>97,742</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>96,399</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:48.48%><P style='font:11pt Times New Roman;margin:0'>Property &amp; Equipment, Net</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>9,721</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>9,908</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>9,945</P>
</TD></TR>
<TR><TD valign=top style=width:48.48%><P style='font:11pt Times New Roman;margin:0'>Intangible Assets, Net</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>14,283</FONT></P>
</TD><TD valign=top style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>14,892</FONT></P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>16,175</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:48.48%><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Assets</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>$124,382</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>$122,542</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>$122,519</P>
</TD></TR>
<TR><TD valign=top style=width:48.48%><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Liabilities &amp; Stockholders&#8217; Equity</FONT></P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:48.48%><P style='font:11pt Times New Roman;margin:0'>Accounts Payable</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>1,194</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>911</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>914</P>
</TD></TR>
<TR><TD valign=top style=width:48.48%><P style='font:11pt Times New Roman;margin:0'>REPAT Tax Payable</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>698</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:48.48%><P style='font:11pt Times New Roman;margin:0'>Other Accrued Liabilities</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2,311</FONT></P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1,687</FONT></P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2,712 </FONT></P>
</TD></TR>
<TR><TD valign=top style=width:48.48%><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;Total Current Liabilities</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'> 3,505</P>
</TD><TD valign=top style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;2,598</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;4,324</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:48.48%><P style='font:11pt Times New Roman;margin:0'>Deferred Tax Liability &#8211;&nbsp;Intangible Assets</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>114</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>493</P>
</TD></TR>
<TR><TD valign=top style=width:48.48%><P style='font:11pt Times New Roman;margin:0'>Long Term Lease Liability</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>210</P>
</TD><TD valign=top style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>225</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>269</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:48.48%><P style='font:11pt Times New Roman;margin:0'>Deferred Revenue and Income Taxes</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>294</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>337</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>386</P>
</TD></TR>
<TR><TD valign=top style=width:48.48%><P style='font:11pt Times New Roman;margin:0'>Stockholders&#8217; Equity</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>120,373</FONT></P>
</TD><TD valign=top style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>119,268</FONT></P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>117,047</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:48.48%><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities &amp; Stockholders&#8217; Equity</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>$124,382</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>$122,542</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>$122,519</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>utmd-20260423_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VAU9GXSW]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20260423"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20260423.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>utmd-20260423_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VAU9GXSW]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20260423"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementTenderOffer' xlink:to='lab_dei_PreCommencementTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityEmergingGrowthCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Emerging Growth Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityEmergingGrowthCompany' xlink:to='lab_dei_EntityEmergingGrowthCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant CIK</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressPostalZipCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Postal Zip Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressPostalZipCode' xlink:to='lab_dei_EntityAddressPostalZipCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressStateOrProvince' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, State or Province</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressStateOrProvince' xlink:to='lab_dei_EntityAddressStateOrProvince'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityShellCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Shell Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityShellCompany' xlink:to='lab_dei_EntityShellCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current with reporting</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_LocalPhoneNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Local Phone Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_LocalPhoneNumber' xlink:to='lab_dei_LocalPhoneNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityTaxIdentificationNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tax Identification Number (TIN)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityTaxIdentificationNumber' xlink:to='lab_dei_EntityTaxIdentificationNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TextBlockAbstract' xlink:to='lab_us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Number of common stock shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Fiscal Year End</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>SEC Form</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressAddressLine1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Address Line One</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressAddressLine1' xlink:to='lab_dei_EntityAddressAddressLine1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityIncorporationStateCountryCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Incorporation, State or Country Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityIncorporationStateCountryCode' xlink:to='lab_dei_EntityIncorporationStateCountryCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityInteractiveDataCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interactive Data Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityInteractiveDataCurrent' xlink:to='lab_dei_EntityInteractiveDataCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CityAreaCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>City Area Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CityAreaCode' xlink:to='lab_dei_CityAreaCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntitySmallBusiness' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Small Business</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntitySmallBusiness' xlink:to='lab_dei_EntitySmallBusiness'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SolicitingMaterial' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Soliciting Material</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SolicitingMaterial' xlink:to='lab_dei_SolicitingMaterial'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SecurityExchangeName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Exchange</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SecurityExchangeName' xlink:to='lab_dei_SecurityExchangeName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFileNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity File Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFileNumber' xlink:to='lab_dei_EntityFileNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityExTransitionPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Ex Transition Period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityExTransitionPeriod' xlink:to='lab_dei_EntityExTransitionPeriod'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_WrittenCommunications' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Written Communications</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_WrittenCommunications' xlink:to='lab_dei_WrittenCommunications'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementIssuerTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Issuer Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementIssuerTenderOffer' xlink:to='lab_dei_PreCommencementIssuerTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressCityOrTown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, City or Town</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressCityOrTown' xlink:to='lab_dei_EntityAddressCityOrTown'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Voluntary filer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Period End date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>utmd-20260423_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VAU9GXSW]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20260423"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20260423.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentType' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_TradingSymbol' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SecurityExchangeName' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityTaxIdentificationNumber' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityInteractiveDataCurrent' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityShellCompany' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntitySmallBusiness' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityEmergingGrowthCompany' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityExTransitionPeriod' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityIncorporationStateCountryCode' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFileNumber' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressAddressLine1' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressCityOrTown' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressStateOrProvince' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressPostalZipCode' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CityAreaCode' use='optional' order='27.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_LocalPhoneNumber' use='optional' order='28.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_WrittenCommunications' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SolicitingMaterial' use='optional' order='30.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementTenderOffer' use='optional' order='31.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementIssuerTenderOffer' use='optional' order='32.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='33.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>utmd-20260423.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VAU9GXSW]. www.edgarsuite.com -->
<schema attributeFormDefault='unqualified' elementFormDefault='qualified' targetNamespace='http://utahmed.com/20260423' xmlns='http://www.w3.org/2001/XMLSchema' xmlns:xbrli='http://www.xbrl.org/2003/instance' xmlns:fil='http://utahmed.com/20260423' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' xmlns:dei='http://xbrl.sec.gov/dei/2025'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20260423_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20260423_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20260423_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='https://www.xbrl.org/dtr/type/2024-01-31/types.xsd' namespace='http://www.xbrl.org/dtr/type/2024-01-31'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='https://xbrl.sec.gov/dei/2025/dei-2025.xsd' namespace='http://xbrl.sec.gov/dei/2025'/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Apr. 23, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Registrant CIK</a></td>
<td class="text">0000706698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">UTAH MEDICAL PRODUCTS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">SEC Form</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Period End date</a></td>
<td class="text">Apr. 23,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Tax Identification Number (TIN)</a></td>
<td class="text">87-0342734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-12575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7043 South 300 West<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Midvale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">566-1200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>19</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="utmd-20260423_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>utmd-20260423.xsd</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="utmd-20260423_8k.htm">utmd-20260423_8k.htm</File>
    <File>utmd-20260423_def.xml</File>
    <File>utmd-20260423_lab.xml</File>
    <File>utmd-20260423_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="19">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "utmd-20260423_8k.htm": {
   "nsprefix": "fil",
   "nsuri": "http://utahmed.com/20260423",
   "dts": {
    "schema": {
     "local": [
      "utmd-20260423.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "inline": {
     "local": [
      "utmd-20260423_8k.htm"
     ]
    },
    "definitionLink": {
     "local": [
      "utmd-20260423_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "utmd-20260423_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "utmd-20260423_pre.xml"
     ]
    }
   },
   "keyStandard": 19,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 34,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 19
   },
   "report": {
    "R1": {
     "role": "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation",
     "longName": "000010 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "D260423",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20260423_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D260423",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20260423_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fiscal Year End",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period End date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Form",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registrant CIK",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of common stock shares outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current with reporting",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Identification Number (TIN)",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Voluntary filer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Exchange",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Details"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://utahmed.com/20260423/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001096906-26-000602-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001096906-26-000602-xbrl.zip
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MI4=(DXJ)RCWN3@DC2?L#YNBV/TA;AI4WLE9F0N<P/J4;=4-7%\S6;_V[-#Q
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MI%K\,ALT$#UT\K\RJ/X&4$L#!!0    ( #9^EUP9'[/5)0@  -).   5
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M_)1=^U/V.1YYD5P#?WIVTOWMP]79U3WK='3CW>'9R;O#6P#YI26;+RPI_G)
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M"B^)>8C >VY'V>LY\,.!/\B!QO3<GM-NLP;8;O:/^_.BUZ5+3<WIP=\/%25
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MLG! )$$4,SH4$I380#U0?EN"3=W_"DL4%?YY[!W+Y;VP/PFY=I08 MSASGY
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MIX\G__%_4$L! A0#%     @ -GZ77&?>;:S. @  ] @  !$
M ( !     '5T;60M,C R-C T,C,N>'-D4$L! A0#%     @ -GZ77-.MVL5R
M#@  _6$  !0              ( !_0(  '5T;60M,C R-C T,C-?.&LN:'1M
M4$L! A0#%     @ -GZ77%BR??X8 @  )@<  !4              ( !H1$
M '5T;60M,C R-C T,C-?9&5F+GAM;%!+ 0(4 Q0    ( #9^EUP9'[/5)0@
M -).   5              "  >P3  !U=&UD+3(P,C8P-#(S7VQA8BYX;6Q0
M2P$"% ,4    "  V?I=<AU(E4JH%  !&-   %0              @ %$'
M=71M9"TR,#(V,#0R,U]P<F4N>&UL4$L! A0#%     @ -GZ77+V#K1\D)@
M=,\   \              ( !(2(  '5T;61?97@Y.7HQ+FAT;5!+!08
.!@ & (<!  !R2      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>utmd-20260423_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="utmd-20260423.xsd" xlink:type="simple"/>
    <context id="D260423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2026-04-23</startDate>
            <endDate>2026-04-23</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="D260423" id="fact1">0000706698</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="D260423" id="fact2">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="D260423" id="ixv-337">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="D260423" id="ixv-338">2026-04-23</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="D260423" id="ixv-339">UTAH MEDICAL PRODUCTS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="D260423" id="ixv-340">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="D260423" id="ixv-341">000-12575</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="D260423" id="ixv-342">87-0342734</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="D260423" id="ixv-343">7043 South 300 West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="D260423" id="ixv-344">Midvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="D260423" id="ixv-345">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="D260423" id="ixv-346">84047</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="D260423" id="ixv-347">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="D260423" id="ixv-348">566-1200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="D260423" id="ixv-349">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="D260423" id="ixv-350">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="D260423" id="ixv-351">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="D260423" id="ixv-352">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="D260423" id="ixv-353">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
